Reactive oxidative species (ROS)-based nanomedicine for BBB crossing and glioma treatment: current status and future directions.

Glioma is the most common primary intracranial tumor in adults with poor prognosis. Current clinical treatment for glioma includes surgical resection along with chemoradiotherapy. However, the therapeutic efficacy is still unsatisfactory.